Close
Back to mobile site

BMO Capital Reiterates Outperform on Bristol-Myers Squibb (BMY)

January 25, 2019 8:45 AM EST Send to a Friend
BMO Capital analyst, Alex Arfaei, reiterated an Outperform rating and $60.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY) following ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login